The therapeutic community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a significant substantial decrease in body size and improve metabolic function,